NovoEight

Selected form

Turoctocog Alfa

Method of action: Antihemorrhagics

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of NovoEight

NovoEight is a prescription medicine used for the treatment and prevention of bleeding episodes in individuals with hemophilia A (congenital Factor VIII deficiency). This genetic disorder prevents blood from clotting properly due to a lack of functional Factor VIII (FVIII) protein. NovoEight works as a replacement therapy, temporarily supplying the missing FVIII to enable blood to clot properly.

Property	Description
Brand Name	NovoEight^ inyregistered
Active Ingredient (INN)	Turoctocog alfa (Antihemophilic Factor, recombinant)
Pharmacological Class	Coagulation Factor (Hemostatic Agent)
Form	Lyophilized powder for injection (given intravenously)
Manufacturer	Novo Nordisk (Denmark)
Availability	Prescription-only (Rx)

Key Features and Treatment Use

The active ingredient in NovoEight is turoctocog alfa, which is a recombinant FVIII protein. It is produced using advanced biotechnology in a lab without the addition of any human- or animal-derived protein in the cell culture or final formulation. This production method is clinically recognized for contributing to a high-purity product profile.

NovoEight is approved for use in both adults and children with hemophilia A for routine prophylaxis (prevention) and on-demand treatment of bleeding, such as a spontaneous muscle bleed or a bleed requiring management during or after surgery. NovoEight is considered a standard half-life FVIII treatment. One of its distinguishing factors is its stability, which allows for storage at a higher temperature for a certain period of time compared with some other recombinant Factor VIII products, offering greater flexibility for patients.

Regulatory References

What side effects are possible with NovoEight?

Possible Side Effects and Safety Information

NovoEight (turoctocog alfa) is a Factor VIII replacement therapy with an officially documented safety profile focusing primarily on immune response and hypersensitivity.

Key Adverse Reaction Categories

Immune Response and Inhibitor Development: The most critical safety consideration is the potential for the body to develop neutralizing antibodies (inhibitors) against Factor VIII, which can reduce the medicine's effectiveness. This event is classified as common in Previously Untreated Patients (PUPs), a specific population known to have the highest risk.

Hypersensitivity and Allergic Reactions: Allergic responses may occur, ranging from minor reactions to rare, severe events such as anaphylaxis. These are documented under Immune System Disorders.

Commonly Reported Reactions: More frequently observed adverse reactions include pyrexia (fever), localized injection site reactions (such as swelling or itching), and an increase in hepatic enzymes, as listed in official prescribing information.

Regulatory Safety Notes

Time-Related Pattern: Regulatory documents explicitly state that the risk of developing Factor VIII inhibitors is highest within the first 50 exposure days to the product.

Contraindication: NovoEight is contraindicated for use in individuals with known life-threatening hypersensitivity to the active substance, its components, or to hamster proteins (a trace residue from the manufacturing process).

Population Note: Patients with established cardiovascular risk factors should note the documented observation that Factor VIII replacement therapy may increase this risk. Additionally, for patients administered the medicine via a Central Venous Access Device (CVAD), the official label includes safety notes regarding potential CVAD-related complications like local infection or bacteraemia.

Overdose and Emergency Response

Overdose and when to seek help

The information regarding overdose for NovoEight (turoctocog alfa) is based strictly on descriptions provided in regulatory documents, such as the Summary of Product Characteristics (SmPC) and the FDA Prescribing Information.

Documented Manifestations and Risks

Category	Regulatory Statement
Physiological Finding	The primary physiological consequence of overdosage is a sustained elevation of plasma Factor VIII activity levels.
Severe Outcome Risk	Overdosage may carry a theoretical risk of thromboembolic events (blood clot formation) due to excessively high plasma Factor VIII levels.

Emergency Actions and Management

Regulatory authorities mandate specific actions if an overdose is suspected:

Seek immediate medical attention or contact emergency services straight away.
It is officially stated that no specific antidote is known for turoctocog alfa.
Management of overdosage consists primarily of symptomatic and supportive treatment.
Careful monitoring of replacement therapy is required in all suspected overdose situations.

Population Considerations

No unique or distinct overdose considerations for specific patient populations (e.g., pediatric or elderly individuals) are formally documented in the official regulatory sections regarding the management of NovoEight overdosage. The overall required action remains the immediate seeking of professional medical assistance.

Therapeutic Uses of NovoEight

NovoEight is a specialized medication applied across therapeutic domains where additional symptomatic support is needed for patients with Hemophilia A, a genetic bleeding disorder. The treatment is commonly used across conditions presenting with acute episodes of bleeding related to this condition.

NovoEight is used in adults and children across three main clinical contexts: on-demand treatment of bleeding episodes, routine prophylaxis, and management in the perioperative setting (during and after surgery). This treatment is vital for managing symptoms that create noticeable physiological strain, such as joint or muscle bleeding, which interfere with routine activities.

The treatment contributes to improved comfort during periods of heightened symptoms and helps with the management of bleeding symptoms that appear suddenly or fluctuate. Used as prophylaxis, the therapy may assist with managing the frequency of symptoms. It also may be part of symptomatic management in the perioperative context for managing heightened systemic burden. Overall, this supportive relief may assist with maintaining functional stability during symptomatic phases.

Quick Fact: Is commonly used to help with Symptoms related to physical discomfort (joint and muscle bleeding)

Eligibility and Restrictions for Use

Eligibility scope

Populations for whom use is allowed (as stated in label):

Adults and Children with congenital Factor VIII deficiency (Hemophilia A).

Populations for whom use is not recommended (if applicable):

Previously Untreated Patients (PUPs): Safety and effectiveness have not yet been established in this specific patient group.

Populations for whom use is contraindicated:

Patients who have had a life-threatening hypersensitivity reaction (including anaphylaxis) to NovoEight or any of its components.
Patients with a known allergy to hamster proteins (present in trace amounts in the product).

Age-related eligibility rules:

The product is officially approved for use across all age groups, though data is limited for older adults (65 years and over).

Condition-specific eligibility rules:

NovoEight is not indicated for the treatment of von Willebrand disease.
In patients who develop Factor VIII inhibitors, the therapy may no longer be effective.

Pregnancy and lactation eligibility status (if explicitly documented):

Use during pregnancy and lactation should occur only if clearly indicated, due to the lack of adequate and well-controlled human studies.

Eligibility classifications (high-level)

Eligibility Severity	Regulatory Basis (Classification)
Absolute Exclusion	Known Hypersensitivity / Hamster Protein Allergy (Contraindicated)
Established Use	Adults and Children with Hemophilia A (Indicated)
Conditional/Limited Use	Pregnancy, Lactation, PUPs, High-titer Inhibitors (Not Established/Only if Clearly Indicated)

Resulting eligibility structure

Official regulatory documents define the eligible population as adults and children with Hemophilia A. The primary restriction is the contraindication against use in patients with known severe allergies to the drug or its components. Use is officially constrained for Previously Untreated Patients (PUPs) and during pregnancy/lactation, where insufficient data requires that use be limited to situations where it is clearly necessary. The medicine is also officially not indicated for von Willebrand disease.

What should I know about interactions with other medicines?

The official regulatory profile for NovoEight (turoctocog alfa) is defined by the absence of formal interaction studies. Authoritative government prescribing information, including the European Summary of Product Characteristics, explicitly states that no specific drug-drug, drug-food, or drug-substance interaction studies have been conducted with turoctocog alfa. This results in a regulatory label that does not document any established interaction patterns.

Official Interaction Findings

Since no specific interaction data is available, the prescribing information contains no details for conventional interaction categories:

Metabolic and Exposure Interactions: The label does not identify any medicines that act as inhibitors or inducers of major cytochrome P450 (CYP) enzymes, and therefore lists no substances known to formally increase or reduce the plasma exposure or clearance of turoctocog alfa.
Pharmacodynamic Effects: No specific additive or synergistic pharmacodynamic effects with co-administered medicinal products are documented in the official government labels.
Food, Alcohol, and Supplements: The label does not state any restrictions or known interactions involving food, alcoholic beverages, or herbal products.
Administration Timing Rules: There are no mandatory timing separation rules or administration constraints listed in the prescribing information for co-administration with other treatments.

The regulatory structure of this section is thus characterized by the non-existence of specific constraints related to pharmacokinetic or pharmacodynamic pathways.

Mechanism of Action

The mechanism of NovoEight (Turoctocog alfa) is one of protein substitution, which functions to facilitate the physiological process of blood coagulation. Its action is strictly confined to the vascular system, where it provides the coagulation co-factor required for proper function.

Co-factor Replacement and Protection

Turoctocog alfa functions as a replacement Factor VIII (FVIII) co-factor. Upon entering circulation, the molecule immediately binds to the endogenous Von Willebrand Factor (VWF). VWF binds to the replacement protein for circulation, transport, and stabilization, supporting its participation in the coagulation cascade.

Assembly of the Tenase Complex

The inactive FVIII must first be converted into the active form, FVIIIa, by trace amounts of thrombin. FVIIIa then functions as an essential molecular co-factor, rapidly assembling with activated Factor IX (FIXa) on the surface of activated platelets to form the tenase complex . This complex is a key assembly within the intrinsic pathway, significantly accelerates the rate of conversion of Factor X (FX) into Factor Xa (FXa).

Cascade Amplification and Fibrin Generation

The resulting surge of FXa amplifies the common pathway, leading to a localized and rapid production of thrombin. Thrombin then performs the final step, cleaving soluble fibrinogen into insoluble fibrin monomers. These monomers polymerize into a stable fibrin meshwork, forming a hemostatic plug that functions to stop blood flow.

Dosage and Administration Information

How NovoEight is Used: Administration Guidelines

NovoEight (turoctocog alfa) is administered only by intravenous (IV) injection following a specific procedural protocol.

Administration and Preparation

The medication is supplied as a lyophilized powder and must be reconstituted using the supplied 0.9% sodium chloride diluent. To prepare, both the powder and the diluent must be brought to room temperature before mixing. The final solution must be visually inspected, and if any particulate matter or discoloration is present, it must not be used. The solution is then injected slowly over 2 to 5 minutes. It is essential that the product is not administered in the same tubing or container with other medicinal products.

Dosing Principles and Schedules

Dosing is strictly individualized, determined by a formula based on the patient’s body weight and the desired increase in Factor VIII (FVIII) activity. This ensures the precise FVIII level is achieved for the specific clinical context.

Usage Patterns:

Routine Prophylaxis: Typically involves a fixed schedule, such as three times weekly or every other day for adults and adolescents.
On-Demand Treatment: Requires repeating the calculated dose every 8 to 24 hours to maintain FVIII targets until the bleeding episode or surgical requirement is managed.

Population-Specific Notes

Pediatric patients (under 12 years) may require a higher or more frequent dose for routine prophylaxis due to a higher drug clearance rate compared to adults. No specific dosing experience or guidance is provided for geriatric patients.

Recent Clinical Evidence

NovoEight: Recent Clinical Evidence

The clinical evidence for NovoEight (turoctocog alfa) is based primarily on a series of large multicenter Phase 3 clinical trials, known as the guardian™ program. These studies are generally open-label and non-comparative, meaning results were not measured directly against a separate treatment or placebo.

Evidence for Use in Treating Bleeding Episodes

Research studied NovoEight for treating sudden bleeding episodes by examining the immediate hemostatic response. This response is a predefined score used to monitor patterns related to achieving stable clotting. Studies reported patterns where the hemostatic response was frequently rated as "excellent" or "good." The lack of head-to-head comparisons limits the insight provided by the research relative to other available treatments.

Evidence for Use in Routine Bleeding Prevention (Prophylaxis)

Studies explored NovoEight in the context of routine prophylaxis, examining patterns over time. The primary outcome measured was the Annualized Bleeding Rate (ABR), which tracks the average number of bleeding episodes per year. Findings describe patterns observed in ABR for those on a consistent administration schedule. Evidence was also collected on patient-reported outcomes describing perceived discomfort. A key limitation is that the research structure was conducted without a concurrent control or placebo group for ABR measurement.

Evidence in Specific Populations and Long-Term Studies

NovoEight was evaluated in specific populations, including children and adolescents, with research also exploring previously untreated patients (PUPs). Data for certain groups, particularly PUPs, remain insufficient compared to the evidence for previously treated patients. Long-term patterns were explored through extension trials that followed patients for multiple years, providing continuous descriptive data on exposure trends. Long-term outcomes related to joint function over many decades are not fully established by the existing trial data.

Frequently Asked Questions (FAQ)

Common questions about NovoEight (FAQ)

Q: Can NovoEight cause a serious allergic reaction, and what are the signs?

A: Yes, official product information states that NovoEight can cause serious allergic reactions, including a severe event called anaphylaxis. Potential signs of a severe reaction can include hives, difficulty breathing, chest tightness, swelling of the lips or tongue, and feelings of dizziness or loss of consciousness.

Q: Can patients with pre-existing health conditions, like liver problems, use NovoEight?

A: Official documents do not contain specific warnings for pre-existing conditions like liver or kidney disease. However, the label does note that increased hepatic enzymes is a frequently reported adverse reaction. Official information indicates that Factor VIII replacement therapy may carry an increased risk for patients with established cardiovascular risk factors.

Q: What kind of clinical research has been conducted on using NovoEight during surgical procedures?

A: Clinical studies assessed the use of NovoEight for perioperative management, which means managing Factor VIII levels during and after surgery. The official dosing guidelines provide recommended Factor VIII activity levels needed to manage both minor and major surgical procedures.

Q: What should be done if NovoEight is accidentally frozen or exposed to high heat?

A: Regulatory guidelines strictly state that NovoEight must not be frozen and should not be returned to refrigeration once it has been stored at room temperature. The reconstituted solution has a maximum use time of 4 hours at room temperature. These specific storage constraints are defined to help maintain the quality and stability of the product.

Q: Why is NovoEight given as an injection rather than a pill?

A: NovoEight is a replacement protein (Factor VIII) which is required to enter the bloodstream directly to function properly in the coagulation cascade. Because proteins are broken down by the digestive system, the medicine is administered via intravenous (IV) injection rather than a pill.

Q: How long has NovoEight been approved and available for patient use?

A: NovoEight was approved in the United States by the Food and Drug Administration (FDA) on November 30, 2018, when it received its Biologics License Application (BLA) approval.

Q: Can NovoEight affect a person's blood pressure or heart rate?

A: Official information indicates that NovoEight can affect the heart rate and blood pressure when a person experiences a severe allergic reaction. Fast heartbeat and hypotension (low blood pressure) are specifically listed as potential symptoms of a hypersensitivity reaction.

Q: Is fatigue or dizziness a possible side effect listed for NovoEight?

A: Dizziness and light-headedness are listed in official documents as potential signs that a person may be having a serious allergic or hypersensitivity reaction. These symptoms are not noted among the most frequently reported general adverse reactions, such as fever or injection site reactions.

Q: Is it true that Factor VIII treatments can sometimes cause a temporary feeling of warmth or redness?

A: Swelling and itching at the injection site are common localized reactions noted in official information. Additionally, signs of a severe allergic reaction can include redness or swelling of the face or hands.

Q: How is the potency of NovoEight measured and standardized?

A: The potency of NovoEight is measured and standardized globally in International Units (IU). This unit of measurement is based on the Factor VIII activity found in one milliliter of normal human plasma.

Q: Does NovoEight have a 'Black Box Warning' in its official documents?

A: According to the official U.S. Prescribing Information, NovoEight does not contain a Boxed Warning. A Boxed Warning is a specific type of caution placed at the beginning of some drug labels to highlight serious safety concerns.

How should NovoEight be stored and disposed of?

Storage and Disposal Requirements

NovoEight (Antihemophilic Factor, Recombinant) must be stored strictly according to regulatory guidelines to maintain stability.

Storage Condition	Requirements
Unopened Vial	Store refrigerated at 36°F to 46°F (2°C to 8°C). May be stored at room temperature (up to 86°F / 30°C) for a single period up to 12 months, or up to 104°F (40°C) for up to 3 months.
Handling	Do not freeze and do not return to refrigeration once stored at room temperature. Keep the vial in its original carton to protect from light.
Reconstituted Solution	Must be used immediately. If not, discard after a maximum of 4 hours (at leq 86^circF / 30^circC) or 2 hours (at leq 104^circF / 40^circC).
Disposal	Dispose of used syringes, needles, and any unused reconstituted product safely in an appropriate sharps container according to local regulations.